Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma

Shino Sato, Kazuyuki Hirooka, Tetsuya Baba, Masanori Mizote, Takashi Fujimura, Kaori Tenkumo, Hirokazu Ueda, Fumio Shiraga

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: The aim of this study was to evaluate the efficacy and safety of bimatoprost in Japanese patients with normal-tension glaucoma (NTG) who showed insufficient response to latanoprost. Methods: A prospective, nonrandomized study was conducted in patients with NTG, with ≤20% intraocular pressure (IOP) decrease from pretreatment baseline with latanoprost monotherapy who had been switched to bimatoprost. The IOP was measured at 4, 8, and 12 weeks after the switch to bimatoprost. In 12 weeks after the switch to bimatoprost, efficacy and safety were evaluated. Results: Postswitch to bimatoprost, IOP was significantly reduced at every visit. Bimatoprost produced significantly greater mean% IOP reduction rate from pretreatment than that of latanoprost at week 12 (P2=0.374; P=0.007). No significant difference was observed in the mean scores of conjunctival hyperemia and corneal epithelial disorder between bimatoprost-treated eyes and latanoprost-treated eyes. Conclusions: Significant additional IOP lowering was achieved by switching to bimatoprost in Japanese patients with NTG with insufficient response to latanoprost. Bimatoprost treatment was safe and well tolerated.

Original languageEnglish
Pages (from-to)499-502
Number of pages4
JournalJournal of Ocular Pharmacology and Therapeutics
Volume27
Issue number5
DOIs
Publication statusPublished - Oct 1 2011
Externally publishedYes

Fingerprint

latanoprost
Low Tension Glaucoma
Safety
Intraocular Pressure
Bimatoprost
Hyperemia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Ophthalmology
  • Pharmacology

Cite this

Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma. / Sato, Shino; Hirooka, Kazuyuki; Baba, Tetsuya; Mizote, Masanori; Fujimura, Takashi; Tenkumo, Kaori; Ueda, Hirokazu; Shiraga, Fumio.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 27, No. 5, 01.10.2011, p. 499-502.

Research output: Contribution to journalArticle

Sato, Shino ; Hirooka, Kazuyuki ; Baba, Tetsuya ; Mizote, Masanori ; Fujimura, Takashi ; Tenkumo, Kaori ; Ueda, Hirokazu ; Shiraga, Fumio. / Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma. In: Journal of Ocular Pharmacology and Therapeutics. 2011 ; Vol. 27, No. 5. pp. 499-502.
@article{320f96dc4ff84de49b8eac15c4f38231,
title = "Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma",
abstract = "Purpose: The aim of this study was to evaluate the efficacy and safety of bimatoprost in Japanese patients with normal-tension glaucoma (NTG) who showed insufficient response to latanoprost. Methods: A prospective, nonrandomized study was conducted in patients with NTG, with ≤20{\%} intraocular pressure (IOP) decrease from pretreatment baseline with latanoprost monotherapy who had been switched to bimatoprost. The IOP was measured at 4, 8, and 12 weeks after the switch to bimatoprost. In 12 weeks after the switch to bimatoprost, efficacy and safety were evaluated. Results: Postswitch to bimatoprost, IOP was significantly reduced at every visit. Bimatoprost produced significantly greater mean{\%} IOP reduction rate from pretreatment than that of latanoprost at week 12 (P2=0.374; P=0.007). No significant difference was observed in the mean scores of conjunctival hyperemia and corneal epithelial disorder between bimatoprost-treated eyes and latanoprost-treated eyes. Conclusions: Significant additional IOP lowering was achieved by switching to bimatoprost in Japanese patients with NTG with insufficient response to latanoprost. Bimatoprost treatment was safe and well tolerated.",
author = "Shino Sato and Kazuyuki Hirooka and Tetsuya Baba and Masanori Mizote and Takashi Fujimura and Kaori Tenkumo and Hirokazu Ueda and Fumio Shiraga",
year = "2011",
month = "10",
day = "1",
doi = "10.1089/jop.2011.0020",
language = "English",
volume = "27",
pages = "499--502",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma

AU - Sato, Shino

AU - Hirooka, Kazuyuki

AU - Baba, Tetsuya

AU - Mizote, Masanori

AU - Fujimura, Takashi

AU - Tenkumo, Kaori

AU - Ueda, Hirokazu

AU - Shiraga, Fumio

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Purpose: The aim of this study was to evaluate the efficacy and safety of bimatoprost in Japanese patients with normal-tension glaucoma (NTG) who showed insufficient response to latanoprost. Methods: A prospective, nonrandomized study was conducted in patients with NTG, with ≤20% intraocular pressure (IOP) decrease from pretreatment baseline with latanoprost monotherapy who had been switched to bimatoprost. The IOP was measured at 4, 8, and 12 weeks after the switch to bimatoprost. In 12 weeks after the switch to bimatoprost, efficacy and safety were evaluated. Results: Postswitch to bimatoprost, IOP was significantly reduced at every visit. Bimatoprost produced significantly greater mean% IOP reduction rate from pretreatment than that of latanoprost at week 12 (P2=0.374; P=0.007). No significant difference was observed in the mean scores of conjunctival hyperemia and corneal epithelial disorder between bimatoprost-treated eyes and latanoprost-treated eyes. Conclusions: Significant additional IOP lowering was achieved by switching to bimatoprost in Japanese patients with NTG with insufficient response to latanoprost. Bimatoprost treatment was safe and well tolerated.

AB - Purpose: The aim of this study was to evaluate the efficacy and safety of bimatoprost in Japanese patients with normal-tension glaucoma (NTG) who showed insufficient response to latanoprost. Methods: A prospective, nonrandomized study was conducted in patients with NTG, with ≤20% intraocular pressure (IOP) decrease from pretreatment baseline with latanoprost monotherapy who had been switched to bimatoprost. The IOP was measured at 4, 8, and 12 weeks after the switch to bimatoprost. In 12 weeks after the switch to bimatoprost, efficacy and safety were evaluated. Results: Postswitch to bimatoprost, IOP was significantly reduced at every visit. Bimatoprost produced significantly greater mean% IOP reduction rate from pretreatment than that of latanoprost at week 12 (P2=0.374; P=0.007). No significant difference was observed in the mean scores of conjunctival hyperemia and corneal epithelial disorder between bimatoprost-treated eyes and latanoprost-treated eyes. Conclusions: Significant additional IOP lowering was achieved by switching to bimatoprost in Japanese patients with NTG with insufficient response to latanoprost. Bimatoprost treatment was safe and well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=80054875685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054875685&partnerID=8YFLogxK

U2 - 10.1089/jop.2011.0020

DO - 10.1089/jop.2011.0020

M3 - Article

VL - 27

SP - 499

EP - 502

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 5

ER -